The influence of mifepristone to caspase 3 expression in adenomyosis

Clin Exp Obstet Gynecol. 2014;41(2):154-7.

Abstract

Objective: To discuss the influence of mifepristone to caspase 3 expression in adenomyosis tissue.

Materials and methods: Sixty patients were equally divided into four groups. Groups 1, 2, and 3 were treated with 5, 10, and 15 mg mifepristone, respectively and group 4 was treated with placebo. The expression of caspase 3 was examined by immunohistochemical method in both eutopic and ectopic endometria of the 40 cases.

Results: Compared with placebo group, the expression of caspase 3 in both eutopic endometrium and ectopic endometrium in the three treatment groups was significantly increased. There was no difference in the expression of caspase 3 in both eutopic and ectopic endometria between the ten and 25 mg treatment groups, while both the ten and 25 mg treatment groups had a higher expression intensity of caspase 3 in both eutopic and ectopic endometria, compared with the five mg treatment group (p < 0.01).

Conclusion: Mifepristone can increase the expression of caspase 3 in both eutopic and ectopic endometria and initiate cell apoptosis in both eutopic and ectopic endometria. Therefore mifepristone can effectively inhibit the emergence and development of adenomyosis.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adenomyosis / drug therapy*
  • Adenomyosis / surgery
  • Adult
  • Caspase 3 / metabolism*
  • Dose-Response Relationship, Drug
  • Endometrium / metabolism*
  • Female
  • Hormone Antagonists / administration & dosage*
  • Humans
  • Immunohistochemistry
  • Middle Aged
  • Mifepristone / administration & dosage*

Substances

  • Hormone Antagonists
  • Mifepristone
  • Caspase 3